External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology AMCP 2026
Roche and Genentech at

AMCP 2026

April 13 - April 16
Nashville, USA
amcpannual.org
We will be contributing to topics related to
Ophthalmology Neuroscience Oncology Immunology Dermatology Nephrology
Add to calendar
Share feedback
Share page
-
Agenda
Medical Materials
08:30 PM
Duration 60mins Nashville, USA
Real-world persistence, switching, and reinitiation in patients who are on faricimab▼ in the US
Stella Ko, Robert Schuldt, Nicole Bonine, Frank Brodie
Ophthalmology | Neovascular Age Related Macular Degeneration - Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Nashville, USA
IMPACT OF THE ILLINOIS BIOMARKER TESTING LAW ON UTILIZATION IN ADVANCED NON-SMALL CELL LUNG CANCER AND METASTATIC COLORECTAL CANCER PATIENTS
Stella Ko, Tu My To, William B. Wong
Oncology | Non-Small Cell Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:30 PM
Duration 60mins Nashville, USA
Projecting potential annual event and cost savings with omalizumab from the reduction in food allergy reactions in the United States population
Fadoua El Moustaid, Arpamas Seetasith, Karina Raimundo, Fatima Dawod, Olivia Mooney, Rina Lukanova, Dawn Sibanda
Immunology | Food allergy

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Nashville, USA
Better Improvement for Omalizumab Versus Dupilumab/Remibrutinib for Patients With Chronic Spontaneous Urticaria: Week 12 Disease Activity Matching-Adjusted Indirect Comparison
Karina Raimundo, Giselle Mosnaim, Michael Holden, Benjamin L. Trzaskoma, Pranil Raut, Arpamas Seetasith, Jonathan A. Bernstein
Dermatology | Chronic Idiopathic Urticaria

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Nashville, USA
Improved Outcomes, Emergency Visits, and Quality of Life for Patients With Food Allergy on Omalizumab Monotherapy
Arpamas Seetasith, Edwin H. Kim, Sayantani Sindher, Fatima Dawod, Olivia Mooney, Rina Lukanova, Dawn Sibanda, Matthew Greenhawt
Immunology | Food allergy

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:00 PM
Duration 60mins Nashville, USA
Real-World Impact of Discontinuing Ocrelizumab on Healthcare Resource Utilization and Cost Among Older Adult Patients With Multiple Sclerosis in the United States
Elmor D. Pineda, Achal Patel, Danny Sheinson, Zhiyu Xia, Ibraheem Abioye
Neuroscience | Multiple Sclerosis

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:00 PM
Duration 60mins Nashville, USA
Fixed-duration subcutaneous mosunetuzumab is cost-effective compared with alternative novel treatment options in third-line or later follicular lymphoma in the United States
Nilanjan Ghosh, Katherine L Rosettie, David Elsea, Mei Wu, Esprit Ma
Oncology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Nashville, USA
Fixed-duration subcutaneous mosunetuzumab has the lowest total cost of care compared with alternative novel treatment options in third-line or later follicular lymphoma in the United States
Nilanjan Ghosh, Katherine L Rosettie, Mei Wu, Esprit Ma
Oncology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Nashville, USA
Cost-effectiveness analysis of obinutuzumab for the treatment of Lupus Nephritis in the United States
Anisha M. Patel, Katherine L. Rosettie, Fadoua El Moustaid, Jesse Sussell, Carolina Heuser, William F. Pendergraft, Amit Saxena
Nephrology | Lupus nephritis

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Coming soon

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.